| Date | Title | Description |
| 03.02.2026 | Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial | Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial.
The data offer early evidence that the injection can be administered less frequently than ex... |
| 03.02.2026 | Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook | Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products.
The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
Pfizer is looking t... |
| 16.12.2025 | Pfizer’s modest 2026 outlook shows its big investments will take time to pay off | Pfizer forecast modest 2026 guidance as it looks to counter waning Covid product sales and declines from older drugs with longer-term investments in its pipeline.
The company expects adjusted profit of $2.80 to $3 per share next year, and r... |
| 14.11.2025 | Novo Nordisk’s shareholders approve chaotic board overhaul as weight loss market challenges loom | Novo Nordisk last month announced an Extraordinary General Meeting for Nov. 14 to replace its independent board members.
Shareholders approved the changes with 93% voting in favor. The foundation controls over 75% of votes.
Norges Bank Inve... |
| 11.11.2025 | CNBC Daily Open: Days of declines won’t keep AI trade down | Major U.S. indexes rose Monday stateside, but Asia-Pacific markets fell Tuesday.
Sony raised its profit forecast and announced a share buyback.
Fed Governor Stephen Miran said a half-point cut for December is “appropriate.”
The U.S. Senate ... |
| 10.11.2025 | Europe markets close higher as hopes of an end to U.S. government shutdown spill over | LONDON — European stocks rallied on Monday as a deal on a funding package that could end the U.S. government shutdown appears to be getting closer.
The pan-European Stoxx 600 closed the session 1.4% higher, with major bourses and almost all... |
| 10.11.2025 | Stocks making the biggest moves midday: Penn Entertainment, Metsera, Six Flags & more | - |
| 10.11.2025 | Pfizer is buying weight-loss drugmaker Metsera. Why Novo Nordisk is the real winner. | - |
| 06.11.2025 | Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study | Eli Lilly said it will start late-stage trials on its experimental amylin obesity drug next month after it showed encouraging results in a mid-stage study.
The highest dose of the weekly injection, called eloralintide, helped patients with ... |
| 05.11.2025 | Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount | Diabetes and obesity care were a key growth driver, however the company lowered its expectations for growth, citing prescription trends, competition and pricing pressure.
A slew of headwinds has shaken investor confidence in what was once E... |
| 04.11.2025 | Pfizer tops estimates, raises profit guidance even as sales fall | Pfizer reported third-quarter earnings and revenue that topped estimates and hiked its full-year profit outlook as it cuts costs, even as sales for the period fell.
The pharmaceutical giant now expects its full-year adjusted profit to come ... |
| 04.11.2025 | Losses for Big Tech pull Wall Street lower | By DAMIAN J. TROISE, AP Business Writer
NEW YORK (AP) — Stocks fell on Wall Street Tuesday, pulled down by losses in the same big tech companies that have been the main drivers of the market’s rally so far this year.
The downturn pulled eve... |
| 03.11.2025 | Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech | Pfizer said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker’s attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive.
The new suit escalates a heated standoff between Pfizer... |
| 02.11.2025 | Global week ahead: Is Novo Nordisk past ‘peak uncertainty’? | Danish pharmaceutical group Novo Nordisk will release its third-quarter earnings on Wednesday.
CNBC’s Charlotte Reed will travel to Copenhagen to speak with the company’s new CEO after a bumpy few months.
Despite this, Berenberg is positive... |
| 30.10.2025 | European markets negative as ECB holds rates; euro zone growth beats expectations | LONDON — European stocks were lower on Thursday, despite the latest figures showing the bloc’s economy grew more than expected and the European Central Bank’s decision to hold interest rates.
The pan-European Stoxx 600 shed over 0.5% by 1:2... |
| 30.10.2025 | Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar | Eli Lilly reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.
The re... |
| 22.09.2025 | Stocks making the biggest moves midday: Oracle, Apple, Metsera, Compass, Kenvue and more | - |
| 22.09.2025 | Pfizer to buy obesity startup Metsera for $4.9 billion; shares jump on Wall Street — Details here | - |
| 22.09.2025 | US stocks set more records as Wall Street’s relentless rally keeps rolling | By STAN CHOE, AP Business Writer
NEW YORK (AP) — The seemingly relentless rally on Wall Street drove U.S. stocks to more records on Monday.
The S&P 500 rose 0.4% after erasing a modest loss from the morning. The Dow Jones Industrial Ave... |
| 22.09.2025 | Pfizer amps up push into obesity treatments with $4.9B deal for Metsera | By TOM MURPHY
Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5 billion acquisition. Related Articles
Wall Street holds near its record heights... |
| 22.09.2025 | Pfizer покупает американскую Metsera и ее портфель препаратов для лечения ожирения за $7,3 млрд | Pfizer Inc. и Metsera, Inc. сообщили о заключении окончательного соглашения, по которому Pfizer приобретает Metsera — биофармацевтическую компанию на клинической стадии, специализирующуюся на разработке инновационных препаратов для лечения ... |
| 22.09.2025 | Stocks making the biggest premarket moves: Metsera, Compass, Kenvue, Fox and more | - |
| 21.09.2025 | Metsera Acquired by Pfizer in $7.3 Billion Deal to Accelerate Obesity Drug Development | - |
| 08.09.2025 | Stocks close at record highs despite job worries, looming inflation reports | All three major indexes closed at record highs Tuesday as investors moved past concerns about the state of the U.S. economy.
The S&P 500 index settled up 0.27% at 6,512.61, while the Nasdaq Composite gained 0.37% to end the day at 21,87... |
| 07.04.2025 | North America Startup Investment Spiked In Q1 Due To OpenAI, But Seed And Early Stage Fell | 0 Shares Email Facebook Twitter LinkedIn
North America’s startup investment hit $82 billion in the first quarter, driven by continued enthusiasm around generative AI.
The Q1 tally represented the highest quarterly funding level in three yea... |
| 20.03.2025 | With $6.2B Purchase Of Chip Designer Ampere, SoftBank Is Going Big This Year | 0 Shares Email Facebook Twitter LinkedIn
As an investor, SoftBank is known for going big.
That mentality came across clearly Wednesday evening, when the storied tech dealmaker announced it will acquire chip design company Ampere Computing, ... |
| 23.01.2025 | MGX’s AI Role In The US Grows | 2 Shares Email Facebook Twitter LinkedIn
While most of the talk about the White House’s new Stargate Project centered on the three big tech names — OpenAI, SoftBank and Oracle — Abu Dhabi-based investment firm MGX also is poised to play a b... |
| 22.11.2024 | Metsera: $215 Million (Series B) Raised To Develop Medicines For Obesity And Metabolic Diseases | Metsera – a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases – announced the closing of a $215 million Series B funding round to further advance its portfolio of highl... |
| 14.11.2024 | Metsera Raises $215M in Series B Financing | Metsera, a NYC-based clinical-stage biopharmaceutical company, raised $215M in Series B funding.
The round was led by Wellington Management and Venrock, with participation from Fidelity Management and Research Company, Janus Henderson Inves... |
| 13.11.2024 | High-flying Metsera follows phase 1 weight loss data with $215M series B raise | Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in a hefty $215 million series B fundraise.
The biotech said it would use the cash to “further accelerate” a portfolio led by its GLP-1... |
| 28.09.2024 | ARCH Venture Partners: $3+ Billion New Fund Raised To Invest In Next-Gen Biotech Companies | ARCH Venture Partners announced the closing of ARCH Venture Fund XIII, a venture capital fund with over $3 billion to support the founding and growth of early-stage biotechnology companies.
ARCH invests in early-stage companies that prevent... |
| 18.04.2024 | ARCH-backed startup Metsera launches to develop drugs for obesity | - |
| 18.04.2024 | Metsera Launches With $290M in Funding | Metsera, a NYC-based clinical-stage biopharmaceutical company, raised $290M in funding.
The round was led by ARCH Venture Partners with participation from other healthcare investors including F-Prime Capital, GV, Mubadala Capital, Newpath P... |
| - | Metsera | “Metsera is a clinical-stage biopharmaceutical company dedicated to leading the next generation of medicines and solutions for obesity and metabolic diseases.” |
